| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
STING[1]
|
|---|---|
| ln Vitro |
In RAW264.7 cells, LPS-induced NO generation is inhibited by STING-IN-4 (Compound 1) (20 μM; 26 h)[1]. In RAW264.7 cells, STING-IN-4 (2.5–10 μM; 26 h) dramatically reduces iNOS expression [1]. At 49, 52, and 55 °C, STING-IN-4 (5 and 50 μM; 12 h) dramatically lowers STING degradation and may interact with STING to improve its thermal stability [1]. STING-IN-4 (2.5–10 μM; 8 h) prevents LPS-induced STING/IRF3/NF-κB activation [1].
|
| ln Vivo |
STING-IN-4 (Compound 1) (1–9 mg/kg; ip; daily for 3 days) prevents liver damage from LPS-induced in mice and prevents septic mice's liver STING/IRF3/NF-κB activation[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: RAW264.7 cells Tested Concentrations: 2.5, 5 and 10 μM Incubation Duration:Pre-treated for 2 h followed LPS treatment for 6 h or 24 h Experimental Results: Inhibited the expression of iNOS (24 h) . Blocked LPS-induced phosphorylation of TBK1, IRF3, p65, and IκB-α (6 h). |
| Animal Protocol |
Animal/Disease Models: BALB/c mice, LPS-induced acute liver injury model[1]
Doses: 1, 3 and 9 mg/kg Route of Administration: intraperitoneal (ip) injection, daily for 3 days Experimental Results: Dramatically decreased the hemorrhage severity. diminished the levels of alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) induced by LPS. Dramatically decreased the levels of TNF-α, IL-6, and IFN-β compared with mice treated only with LPS. Markedly decreased the levels of STING, p-TBK, p-IRF3, p-p65, and p-IκB-α. |
| References |
| Molecular Formula |
C32H46N2O3
|
|---|---|
| Molecular Weight |
506.72
|
| Exact Mass |
506.35
|
| CAS # |
2250374-27-5
|
| PubChem CID |
155529575
|
| Appearance |
White to off-white solid powder
|
| LogP |
6
|
| tPSA |
83.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
37
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC3=NC=CN=C3[C@@]([C@]1([H])CC[C@]1([C@@]3(CC[C@]4(CCC(C[C@@]4([H])C3=CC[C@]21[H])(C)C)C(=O)O)C)C)(C)CO
|
| InChi Key |
MKLBYRFEFHWRDA-NGTCWZDESA-N
|
| InChi Code |
InChI=1S/C32H46N2O3/c1-27(2)11-13-32(26(36)37)14-12-30(5)20(21(32)17-27)7-8-24-28(3)18-22-25(34-16-15-33-22)29(4,19-35)23(28)9-10-31(24,30)6/h7,15-16,21,23-24,35H,8-14,17-19H2,1-6H3,(H,36,37)/t21?,23?,24?,28-,29-,30+,31+,32-/m0/s1
|
| Chemical Name |
(2R,10S,14R,15S,18S)-10-(hydroxymethyl)-2,10,14,15,21,21-hexamethyl-5,8-diazahexacyclo[12.12.0.02,11.04,9.015,24.018,23]hexacosa-4,6,8,24-tetraene-18-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~93.3 mg/mL (~184.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (35.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (35.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9735 mL | 9.8674 mL | 19.7348 mL | |
| 5 mM | 0.3947 mL | 1.9735 mL | 3.9470 mL | |
| 10 mM | 0.1973 mL | 0.9867 mL | 1.9735 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.